StockCIK 1764013
Immunovant, Inc. (IMVT): Insider Trades and Fund Holdings
In the past 12 months, Immunovant, Inc. insiders reported 0 open-market purchases worth $0 and 8 sales worth $735K; 1 of the sales were reported as made under a 10b5-1 trading plan.
0Insider buys, 12 months
$0Bought by insiders, 12 months
$735KSold by insiders, 12 months
1Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 23, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 23 | Jay S. StoutCTO | ▼ SELL | $75K |
| Oct 9 | Jay S. StoutCTO | ▼ SELL | $122K |
| Oct 9 | Melanie GloriaCOO | ▼ SELL | $72K |
| Oct 9 | Van Tuyl ChristopherGeneral Counsel | ▼ SELL | $43K |
| Oct 5 | Eric VenkerCEO | ▼ SELL | $120K |
| Sep 25 | Van Tuyl ChristopherGeneral Counsel | ▼ SELL | $103K |
| Aug 28 | Atul PandeDirector | ▼ SELL10b5-1 | $65K |
| Aug 21 | Melanie GloriaCOO | ▼ SELL | $135K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Jay S. Stout | CTO | 0 | $0 | 2 | $197K |
| Melanie Gloria | COO | 0 | $0 | 2 | $207K |
| Van Tuyl Christopher | General Counsel | 0 | $0 | 2 | $146K |
| Eric Venker | CEO | 0 | $0 | 1 | $120K |
| Atul Pande | Director | 0 | $0 | 1 | $65K |
ADVERTISEMENT
320 × 100 ad slot
Tracked funds that report IMVT
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 726,800 | $28.0M | ▲ +277.6% |
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →